A LinkedIn post from Forge Biologics highlights the company’s scientific presence at Bioprocessing Summit Europe through the participation of its Vice President of Process Development, Frank Agbogbo, Ph.D. The post notes that Agbogbo is scheduled to chair a session on “Novel Vectors and Capsid Engineering to Improve Production” on Thursday, March 12.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
According to the post, Agbogbo will also present in the Gene Therapy CMC and Analytics track on “Advances in rAAV Manufacturing and Process Characterization.” This focus on improved vector design and recombinant AAV manufacturing suggests ongoing investment in technical leadership and process innovation, which may enhance Forge Biologics’ competitive position in gene therapy manufacturing and support its ability to attract biopharma partners over time.